TrialThe Lancet. Oncology2020

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.

Aleix Prat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.